We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bayer AG | TG:BAYN | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.50 | 1.85% | 27.475 | 27.375 | 27.57 | 27.61 | 26.94 | 26.945 | 404,068 | 22:50:04 |
From Apr 2021 to Apr 2024
By Ed Frankl
Bayer AG said Monday that it will collaborate on novel gene-editing technology with California-based diagnostics company Mammoth Biosceiences.
Mammoth would received an upfront payment of $40 million and potential future milestone payments of more than $1 billion upon successful achievement of certain research, development, and commercial milestones with a first focus on liver-targeted diseases, Bayer said.
The German pharmaceutical conglomerate also said it will pay Mammoth research funding and tiered royalties up to low double-digit percentage of net sales.
"Partnering with Mammoth's cutting-edge scientific team is a fundamental pillar for our company to improve the lives of patients suffering from conditions that are currently still difficult to treat," said Stefan Oelrich, President of Bayer's pharmaceuticals division.
The agreement will allow Bayer to unleash the full potential of its cell- and gene-therapy strategy, Mr. Oelrich added.
Write to Ed Frankl at edward.frankl@dowjones.com
-0-
(END) Dow Jones Newswires
January 10, 2022 04:32 ET (09:32 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Bayer Chart |
1 Month Bayer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
